Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial

Background: Debate exists as to whether statin pretreatment confers an increased risk of 90-day mortality and symptomatic intracranial haemorrhage (sICH) in acute ischaemic stroke (AIS) patients treated with intravenous thrombolysis. We assessed the effects of undifferentiated lipid-lowering pretrea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cerebrovascular diseases (Basel, Switzerland) Switzerland), 2018-01, Vol.45 (5-6), p.213-220
Hauptverfasser:	Minhas, Jatinder S., Wang, Xia, Arima, Hisatomi, Bath, Philip M., Billot, Laurent, Broderick, Joseph P., Donnan, Geoffrey A., Kim, Jong S., Lavados, Pablo M., Lee, Tsong-Hai, Martins, Sheila Cristina Ouriques, Olavarría, Verónica V., Pandian, Jeyaraj D., Pontes-Neto, Octávio Marques, Ricci, Stefano, Sato, Shoichiro, Sharma, Vijay K., Thang, Nguyen H., Wang, Ji-Guang, Woodward, Mark, Chalmers, John, Anderson, Craig S., Robinson, Thompson G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antilipemic agents Biomarkers - blood Brain Ischemia - blood Brain Ischemia - diagnosis Brain Ischemia - drug therapy Brain Ischemia - mortality Care and treatment Disability Evaluation Female Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - adverse effects Health aspects Hospital admission and discharge Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hypertension Infusions, Intravenous Intracranial Hemorrhages - chemically induced Ischemia Lipids - blood Male Middle Aged Morbidity Mortality Original Paper Prospective Studies Risk Factors Statins Stroke Stroke - blood Stroke - diagnosis Stroke - drug therapy Stroke - mortality Thrombolytic Therapy - adverse effects Thrombolytic Therapy - methods Thrombolytic Therapy - mortality Time Factors Tissue plasminogen activator Tissue Plasminogen Activator - administration & dosage Tissue Plasminogen Activator - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!